In this context, it is worth noting that in patients with recurrent GBM, the MTD of Lisavanbulin given as monotherapy was set at 30 mg/day.21 Also, MGMT promoter methylation testing was not performed centrally due to concerns about the delay of the start of radiation in these patients with newly diagnosed GBM. This evidence concerns the gene MGMT and glioblastoma.